期刊名称：JOURNAL OF HEMATOLOGY & ONCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology.
Hematology and oncology are closely intertwined and rapidly evolving fields. More physician scientists performing laboratory-based research are rapidly bringing research in hematology and oncology from bench to bedside. Journal of Hematology & Oncology aims to meet the demand for a journal dedicated to publishing discovery from both of these fields.
Journal of Hematology & Oncology aims to serve as an international platform for sharing laboratory and clinical findings in an open access format among laboratory scientists, physician scientists, hematologists and oncologists. A rapid turnaround time from submission to publication means that knowledge and new successes can be shared in real time.
Instructions to Authors
Criteria for publication
Journal of Hematology & Oncology considers the following types of articles:
Research: reports of data from original research.
Reviews:comprehensive, authoritative, descriptions of any subject within the journal's scope. Reviews can cover any topical themes such as basic science and clinical reviews, ethics, pro/con debates, equipment reviews and thematic series to highlight specific topics in the field.
Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. These can also be used to present unexpected or unusual images of a disease. All case report articles should indicate that informed consent to publish the information was granted from the patients or their guardians.
Letters to the Editor brief laboratory and clinical studies should be submitted in this format for rapid communication. Reports of individual cases which may impact and /or enhance clinical practice or diagnostic understanding can also be submitted in this format. These can also take other forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.
Short reports: brief reports of data from original research.
Peer-review policies
Journal of Hematology & Oncology has a 'closed' peer review policy. All submitted manuscripts will be screened before being sent to two peer reviewers. The Editor-in-Chief and Associate Editors are routinely involved in decision-making, but final decisions lie with the Editor-in-Chief. The journal aims to reach a first decision within six weeks. If an author has queries or is unhappy with a decision, there will be a discussion involving the Editor-in-Chief and at least one of the Associate Editors who were not involved in the initial reviewing.
Edited by Delong Liu, Journal of Hematology & Oncology is supported by an expert Editorial Board.
Peer review
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Journal of Hematology & Oncology, a personalized section of the site.
Portability of peer-review
In order to support efficient and thorough peer review, we aim to reduce the number of times a manuscript is re-reviewed after rejection from Journal of Hematology & Oncology, thereby speeding up the publication process and reducing the burden on peer reviewers. Therefore, please note that, if a manuscript is not accepted for publication in Journal of Hematology & Oncology and the authors choose to submit a revised version to another BioMed Central journal, we will pass the reviews on to the other journal's editors at the authors’ request. We will reveal the reviewers' names to the handling editor for editorial purposes unless reviewers let us know when they return their report that they do not wish us to share their report with another BioMed Central journal.
Reprints
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints, and to enquire about further details, including fees, please contact BioMed Central's reprint service.
Supplements
Journal of Hematology & Oncology will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
Editorial policies
Any manuscript, or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. The journal is willing to consider peer-reviewing manuscripts that are translations of articles originally published in another language. In this case, the consent of the journal in which the article was originally published must be obtained and the fact that the article has already been published must be made clear on submission and stated in the abstract. Further information on duplicate/overlapping publications can be found here. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Correspondence concerning articles published in Journal of Hematology & Oncology is encouraged. A 'post a comment' feature is available on all articles published by Journal of Hematology & Oncology. Comments will be moderated by the editorial office (see our Comment policy for further information) and linked to the full-text version of the article, if suitable.
Editorial standards
BioMed Central is a member of the Committee on Publication Ethics (COPE)and endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.
Ethical guidelines
Submission of a manuscript to Journal of Hematology & Oncology implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body that gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.
Journal of Hematology & Oncology's publisher, BioMed Central, has a legal responsibility to ensure that its journals do not publish material that infringes copyright, or that includes libellous or defamatory content. If, on review, your manuscript is perceived to contain potentially libellous content the journal Editors, with assistance from the publisher if required, will work with authors to ensure an appropriate outcome is reached.
For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be made available if requested by the editorial staff.
The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, their role should be acknowledged explicitly.
Standards of reporting
Journal of Hematology & Oncology supports initiatives aimed at improving the reporting of biomedical research. We recommend authors refer to the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies.
For mutation nomenclature please use the guidelines suggested by the Human Genome Variation Society, and the recommended gene name by consulting the appropriate genetic nomenclature database, e.g., HUGO for human genes, and the International Committee on Standardized Genetic Nomenclature for Mice. We encourage the use of standardized terms for human phenotypes, such as those proposed by the Elements of Morphology working group (see: http://research.nhgri.nih.gov/morphology/index.cgi).
Checklists have also been developed for a number of study designs, including randomized controlled trials (CONSORT), systematic reviews (PRISMA), meta-analyses of observational studies (MOOSE), diagnostic accuracy studies (STARD) and qualitative studies (RATS). We recommend authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research. For authors of systematic reviews, a supplementary file, linked from the Methods section, should reproduce all details concerning the search strategy. For an example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook.
Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.
Journal of Hematology & Oncology also supports initiatives to improve the perfomance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.
Authors of protocols or reports of such clinical trials, where the primary purpose of the research is to understand the causes, development and effects of disease or to improve preventatative, diagnostic or therapeutic interventions, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (http://www.icmje.org/faq.html), the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform.
The trial registration number should be included as the last line of the manuscript abstract.
Data and materials release
Submission of a manuscript to Journal of Hematology & Oncology implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.
Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.
Nucleotide sequences
Nucleotide sequences can be deposited with the DNA Data Bank of Japan (DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database, or GenBank (National Center for Biotechnology Information).
Protein sequences
Protein sequences can be deposited with SwissProt or the Protein Information Resource (PIR).
The accession numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets with the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).
Mass spectrometry
Mass spectrometry data should be supplied in the mzML format recommended by the HUPO Protein Standards Initiative Mass Spectrometry Standards Working Group guidelines (http://www.psidev.info/index.php?q=node/80). We also recommend that the data is deposited in the ProteomeExchange (http://proteomexchange.org/) though the PRIDE website (http://www.ebi.ac.uk/pride/), and protein interaction data can be submitted to members of the IMEx consortium (http://disber.net/imexdrupal/).
Structures
Protein structures can be deposited with one of the members of the Worldwide Protein Data Bank. Nucleic Acids structures can be deposited with the Nucleic Acid Database at Rutgers. Crystal structures of organic compounds can be deposited with the Cambridge Crystallographic Data Centre.
Chemical structures and assays
Structures of chemical substances can be deposited with PubChem Substance. Bioactivity screens of chemical substances can be deposited with PubChem BioAssay.
Microarray data
Where appropriate, authors should adhere to the standards proposed by the Microarray Gene Expression Data Society and must deposit microarray data in MIAME-compliant format in one of the public repositories, such as ArrayExpress, Gene Expression Omnibus (GEO) or the Center for Information Biology Gene Expression Database (CIBEX).
Computational modeling
We encourage authors to prepare models of biochemical reaction networks using the Systems Biology Markup Language and to deposit the model with the BioModels database, as well as submitting it as an additional file with the manuscript.
Plasmids
We encourage authors to deposit copies of their plasmids as DNA or bacterial stocks with Addgene, a non-profit repository, or PlasmID, the Plasmid Information Database at Harvard.
Appeals against rejection
If authors are not satisfied with the decision made on their manuscript, they should contact the Editorial Office with their appeal; additional advice on the manuscript will be sought where appropriate. Authors who have appealed against a rejection but remain concerned about the editorial process can refer their case to COPE.
Competing interests
Journal of Hematology & Oncology requires authors to declare any competing financial or other interest in relation to their work. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
Citing articles in Journal of Hematology & Oncology
Articles in Journal of Hematology & Oncology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Journal of Hematology & Oncology [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Journal of Hematology & Oncology 2009, 1:115.
Why publish your article in Journal of Hematology & Oncology?
High visibility
Journal of Hematology & Oncology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Journal of Hematology & Oncology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browseable web form, and as a formatted PDF; the article will then be available through Journal of Hematology & Oncology, BioMed Central and PubMed Central and will also be included in PubMed.
Flexibility
Online publication in Journal of Hematology & Oncology gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other papers).
Promotion and press coverage
All articles published in Journal of Hematology & Oncology are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Journal of Hematology & Oncology's pages and BioMed Central's homepage.
In addition, articles published in Journal of Hematology & Oncology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Hematology & Oncology. A list of articles recently press-released by journals published by BioMed Central is available here.
Copyright
Authors of articles published in Journal of Hematology & Oncology retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
Editorial Board
Editor-in-Chief
Dr Delong Liu
New York Medical College, United States
Deputy Editors
Dr Zihai Li
Medical University of South Carolina, United States
Prof Ruibao Ren
Brandeis University, United States
Associate Editors
Prof Andre Baruchel
Hospital Saint-Louis, France
Prof Alan Burnett
University of Wales College of Medicine, United Kingdom
Dr Edward Chu
Yale Cancer Center, United States
Prof Jorge Cortes
MD Anderson Cancer Center, United States
Dr Chung-Tsen Hsueh
Loma Linda University, United States
Dr Mary Laughlin
Case Western Reserve University, United States
Dr Raymond Liang
University of Hong Kong, Hong Kong
Dr Lucio Luzzatto
Istituto Toscano Tumori , Italy
Dr Peter Maslak
Memorial Sloan-Kettering Cancer Center, United States
Dr Edith Perez
Mayo Clinic, United States
Dr Ezra Raza
Columbia University Medical Center, United States
Prof Hideyuki HS Saya
Keio University School of Medicine, Japan
Dr Karen Seiter
New York Medical College, United States
Prof Martin Tallman
Memorial Sloan-Kettering Cancer Center, United States
Managing Editor
Dr RuiRong Yuan
University of Medicine and Dentistry, New Jersey, United States
Editorial Board
Dr Ghassan Abou-Alfa
Memorial Sloan-Kettering Cancer Centre, United States
Dr Tauseef Ahmed
New York Medical College, United States
Dr David Chang
MD Anderson Cancer Center, United States
Dr Hong Chang
University of Toronto, Canada
Prof Jen-Wei Chiao
New York Medical College, United States
Dr Muhammad Choudhury
New York Medical College, United States
Dr Hoo G Chun
Catholic University of Korea, South Korea
Prof Alexander Dobrovic
Peter MacCallum Cancer Centre, Australia
Prof Eric Feldman
Weill Medical College of Cornell University, United States
Dr Janice L. Gabrilove
Mt Sinai School of Medicine, United States
Dr Jing-Zhou Hou
University of Pittsburgh Cancer Institute, United States
Prof Sundar Jagannath
Mount Sinai Medical Center, United States
Dr Milind Javle
MD Anderson Cancer Center, United States
Dr Feng-Ming Kong
University of Michigan, United States
Dr Ke Liu
Food and Drug Administration, United States
Dr Janice Lu
SUNY at Stony Brook, United States
Dr Michael J Mauro
Oregon Health and Science University, United States
Dr Sylvain Meloche
Institut de Recherche en Immunologie et Cancérologie, Canada
Dr Owen A O'Connor
Columbia University, United States
Dr Pier Paolo Pandolfi
Harvard Medical School, United States
Prof Shukui Qin
Nanjing Bayi Hospital, China
Prof Fazlul Sarkar
Wayne State University School of Medicine, United States
Dr Wenru Song
Baylor Institute for Immunology Research, United States
Dr Weijing Sun
University of Pennsylvania, United States
Dr Yan Sun
Cancer Hospital/Institue, China
Dr William Tse
University of Colorado School of Medicine, United States
Dr Amit Verma
Albert Einstein College of Medicine, United States
Dr Lu-Hai Wang
Mount Sinai School of Medicine, United States
Dr Shenhong Wu
Stony Brook University Cancer Center, United States
Dr Richard Xu
North Shore University Hospital, United States
Dr Ying Yan
University Missouri, Kansas City, United States
Dr Jeffrey Ye
Kaiser Permanente, United States
Dr Andrew X Zhu
Massachussetts General Hospital, Harvard Medical School, United States
| 
